Opendata, web and dolomites

Chelator SIGNED

IRON CHELATOR NBMI FOR THE TREATMENT OF IRON OVERLOAD IN BETA-THALASSEMIA MAJOR

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Chelator" data sheet

The following table provides information about the project.

Coordinator
NBMI SCIENCE LIMITED 

Organization address
address: TRINITY HOUSE, CHARLESTON ROAD, RANELAGH
city: DUBLIN
postcode: D06 C8X4
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NBMI SCIENCE LIMITED IE (DUBLIN) coordinator 50˙000.00

Map

 Project objective

β-thalassemia major (βTM) is a lethal orphan disease with genetic background, diagnosed in infancy and requiring recurrent blood transfusions to prevent malformations, assure acceptable quality of life and prolong patient’s lifetime. Constant transfusions are related to severe adverse effects due to the resultant iron overload, including severe impairment of internal organs’ function and heart disease, with cardiac complications causing over two thirds of deaths in βTM patients. Life-long, effective iron chelation therapy is the only measure to reduce these risks, but available chelators have low efficacy and tolerability and/or complicated administration route. Together with high costs it hampers compliance, reducing the efficacy of available chelators even more and leaving unmet the need for safe, effective and easy to use iron chelator. Emeramide is an efficient metal chelator shown to decrease iron levels in vitro and in vivo, with a huge advantage of safety already confirmed in clinical trials up to Phase 2a. The drug has been recognized by the US and the EU authorities and received Orphan Drug Designation for mercury toxicity treatment. Thanks to its great tolerability Emeramide promotes high compliance with chelation therapy, making patients’ lives not only longer, but also as close to normal as possible.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHELATOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHELATOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

Cortx (2019)

Intelligent debt recovery platform.

Read More  

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More